Bright Minds Biosciences Inc. ownership update: Vivo Opportunity entities amended beneficial ownership reporting to show combined holdings of certain Vivo funds and general partners. Vivo Opportunity Fund Holdings, L.P. (via Vivo Opportunity, LLC) holds 504,645 shares of Common Stock, representing 5.2% of the class. Vivo Opportunity Cayman Fund, L.P. (via Vivo Opportunity Cayman, LLC) holds 52,527 shares, representing 0.5%. The filing cites 9,787,161 shares outstanding as of February 12, 2026. All reported shares are held of record by the named partnership entities and voting and dispositive powers are stated as sole for each reported amount.
Positive
None.
Negative
None.
Insights
Amendment clarifies beneficial ownership and control by Vivo entities.
Vivo Opportunity Fund Holdings, L.P. is reported as the record holder of 504,645 shares with sole voting and dispositive power; the filing attributes that control to its general partner, Vivo Opportunity, LLC. The filing ties percentages to an explicit outstanding share count dated February 12, 2026.
These disclosures update ownership detail and governance attribution; subsequent changes in holdings would be actionable only if new filings appear. The cash‑flow treatment or any transactions leading to these holdings are not described in the excerpt.
Key Figures
Vivo Fund holdings:504,645 sharesVivo Cayman holdings:52,527 sharesPercent of class (Vivo Fund):5.2%+2 more
5 metrics
Vivo Fund holdings504,645 sharesBeneficial ownership by Vivo Opportunity Fund Holdings, L.P.
Vivo Cayman holdings52,527 sharesBeneficial ownership by Vivo Opportunity Cayman Fund, L.P.
Percent of class (Vivo Fund)5.2%Percent of common stock based on outstanding shares as of <date>February 12, 2026</date>
Percent of class (Vivo Cayman)0.5%Percent of common stock based on outstanding shares as of <date>February 12, 2026</date>
Shares outstanding used9,787,161 sharesShares outstanding as of <date>February 12, 2026</date>
Key Terms
beneficially owned, sole dispositive power, Schedule 13G/A
3 terms
beneficially ownedregulatory
"Amount beneficially owned: Vivo Opportunity, LLC beneficially owns 504,645 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive powerregulatory
"Sole Dispositive Power 504,645.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13G/Aregulatory
"Item 1. | (a) | Name of issuer: Bright Minds Biosciences Inc."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Bright Minds Biosciences Inc.
(Name of Issuer)
Common Stock, no par value
(Title of Class of Securities)
10919W405
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
10919W405
1
Names of Reporting Persons
Vivo Opportunity Fund Holdings, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
504,645.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
504,645.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
504,645.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The number represents shares of common stock, no par value (the "Common Stock") of Bright Minds Biosciences Inc. (the "Issuer") held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
The percentage of class is based on 9,787,161 shares of Common Stock outstanding as of February 12, 2026, as reported in the Issuer's Current Report on Form 6-K, filed with the Securities and Exchange Commission (the "SEC") on February 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
10919W405
1
Names of Reporting Persons
Vivo Opportunity, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
504,645.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
504,645.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
504,645.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
The percentage of class is based on 9,787,161 shares of Common Stock outstanding as of February 12, 2026, as reported in the Issuer's Current Report on Form 6-K, filed with the SEC on February 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
10919W405
1
Names of Reporting Persons
Vivo Opportunity Cayman Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
52,527.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
52,527.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
52,527.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.5 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
The percentage of class is based on 9,787,161 shares of Common Stock outstanding as of February 12, 2026, as reported in the Issuer's Current Report on Form 6-K, filed with the SEC on February 13, 2026.
SCHEDULE 13G
CUSIP Number(s):
10919W405
1
Names of Reporting Persons
Vivo Opportunity Cayman, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
52,527.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
52,527.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
52,527.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.5 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
The percentage of class is based on 9,787,161 shares of Common Stock outstanding as of February 12, 2026, as reported in the Issuer's Current Report on Form 6-K, filed with the SEC on February 13, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Bright Minds Biosciences Inc.
(b)
Address of issuer's principal executive offices:
400 N Aberdeen St Suite 900, Chicago, IL 60642
Item 2.
(a)
Name of person filing:
Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC
Vivo Opportunity Cayman Fund, L.P. and its General Partner Vivo Opportunity Cayman, LLC
(b)
Address or principal business office or, if none, residence:
192 Lytton Avenue, Palo Alto, CA 94301
(c)
Citizenship:
Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership.
Vivo Opportunity, LLC is a Delaware limited liability company.
Vivo Opportunity Cayman Fund, L.P. is a Cayman Islands limited partnership.
Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.
(d)
Title of class of securities:
Common Stock, no par value
(e)
CUSIP No.:
10919W405
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Vivo Opportunity, LLC beneficially owns 504,645 shares of Common Stock. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
Vivo Opportunity Cayman, LLC beneficially owns 52,527 shares of Common Stock. The securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
(b)
Percent of class:
Vivo Opportunity Fund Holdings, L.P.: 5.2%
Vivo Opportunity, LLC: 5.2 %
Vivo Opportunity Cayman Fund, L.P.: 0.5%
Vivo Opportunity Cayman, LLC.: 0.5%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Vivo Opportunity Fund Holdings, L.P.: 504,645 shares
Vivo Opportunity, LLC: 504,645 shares
Vivo Opportunity Cayman Fund, L.P.: 52,527 shares
Vivo Opportunity Cayman, LLC: 52,527 shares
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
Vivo Opportunity Fund Holdings, L.P.: 504,645 shares
Vivo Opportunity, LLC: 504,645 shares
Vivo Opportunity Cayman Fund, L.P.: 52,527 shares
Vivo Opportunity Cayman, LLC: 52,527 shares
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Vivo Opportunity Fund Holdings, L.P.
Signature:
/s/ Kevin Dai
Name/Title:
Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:
05/12/2026
Vivo Opportunity, LLC
Signature:
/s/ Kevin Dai
Name/Title:
Kevin Dai/Managing Member
Date:
05/12/2026
Vivo Opportunity Cayman Fund, L.P.
Signature:
/s/ Kevin Dai
Name/Title:
Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
What stake does Vivo Opportunity report in Bright Minds Biosciences (DRUG)?
Vivo Opportunity Fund Holdings, L.P. reports beneficial ownership of 504,645 shares, equal to 5.2% of the outstanding common stock as stated in the filing. This stake is held of record by the named partnership entity.
How many shares does Vivo Opportunity Cayman report owning in DRUG?
Vivo Opportunity Cayman Fund, L.P. reports beneficial ownership of 52,527 shares, equal to 0.5% of the class, with sole voting and dispositive power cited in the amendment.
What outstanding share base does the filing use to compute percentages?
The filing uses an outstanding share count of 9,787,161 shares of common stock, cited as of February 12, 2026, as the denominator for the reported percentages.
Who signed the Schedule 13G/A amendment for these Vivo entities?
The amendment is signed by Kevin Dai in his capacity as Managing Member of the relevant general partner entities, with signature dates shown as May 12, 2026.
